Follow us on Twitter
This page is updated frequently with new Gly-related patent applications. Subscribe to the Gly RSS feed to automatically get the update: related Gly RSS feeds. RSS updates for this page: Gly RSS
|| List of recent Gly-related patents
|Computer-implemented system and method for facilitating accurate glycemic control by modeling blood glucose using circadian profiles|
A computer-implemented system and method for facilitating accurate glycemic control by modeling blood glucose using circadian profiles is provided. Anti-hyperglycemic medications are categorized based on similar glucose lowering effects.
|Synthesis of h-phosphonate intermediates and their use in preparing the herbicide glyphosate|
The esterfication of hypophosphorous acid is followed by reaction with another molecule of alcohol under the action of a nickel catalyst to provide a green method for the preparation of h-phosphonate diesters. This method avoids the need for any stoichiometric chlorine unlike those based on phosphorous trichloride..
|Palm oil enriched in unsaturated fatty acids|
A process for producing a food oil containing at least 50% monounsaturated fatty acids from palm oil is disclosed. Fatty acids are released from palm oil glycerides, such as by fat-splitting.
|Method for producing mixture containing fatty acid monoglyceride|
The present invention relates to a method for producing a mixture containing fatty acid monoglyceride from glycerin and a compound having at least one acyl group, selected from fatty acids and fatty acid glycerides, including: (i) a step of obtaining a mixture containing fatty acid monoglyceride by heating and reacting glycerin and a compound having at least one acyl group, selected from fatty acids and fatty acid glycerides in the presence of a catalyst; (ii) a step including adding glycerin, which is liquid and has a lower temperature than the temperature of the mixture, to the mixture to cool the mixture; and (iii) a step of separating the mixture containing fatty acid monoglyceride from glycerin, obtained in the step (ii), by separating layers.. .
|Phytoglycogen-based compositions, materials and methods|
The present invention provides methods for treating phytoglycogen-containing materials to generate phytoglycogen compositions with enhanced emulsification attribute. One method comprises contacting a phytoglycogen-containing material with at least one protease.
|Stereoselective glycosylation reactions|
Disclosed is a method for selective synthesis of 1,2-cis-α-linked glycosides which does not require the use of the specialized protecting group patterns normally employed to control diastereoselectivity. Thioglycoside acceptors can be used, permitting iterative oligosaccharide synthesis.
|Process for producing acrolein, acrylic acid and derivatives thereof|
A process for producing acrolein, comprising: a glycerin dehydration step of conducting dehydration reaction of glycerin to obtain an acrolein-containing gas; a partial-condensation step of cooling the acrolein-containing gas to condense a part of acrolein, water and a high-boiling substance contained in the acrolein-containing gas, thereby obtaining a purified gas and a condensate; and a separation step of separating the purified gas from the condensate; wherein a polymerization inhibitor is added to the acrolein-containing gas or the condensate in the partial-condensation step.. .
|Method of solubilizing insoluble bioactive compounds using triterpene glycosides and compositions thereof|
Disclosed are the uses of triterpene glycosides as non-toxic natural solubilizing agents for bioactive compounds and/or metabolites thereof. Triterpene glycosides are also shown to solubilize insoluble natural extracts.
|Substituted cyclopenta pyrimidine bicyclic compounds having antitmitotic and/or antitumor activity and methods of use thereof|
And pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example p-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells..
|Solution for oral administration|
Provided is a solution suitable for oral administration of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one (compound (i)) or a salt thereof. A solution for oral administration containing compound (i) or a salt thereof, and at least one compound selected from the group consisting of lactic acid, phosphoric acid, glycolic acid, malic acid, tartaric acid, citric acid, succinic acid and acetic acid and having ph 2.5-4.5..
|Synergistic anti-diabetic compositions|
The present invention is concerned with improved synergistic compositions effective in the treatment of diabetes and/or hyperglycemia. In particular, the present invention is concerned with synergistic compositions comprising inulin preparations having a defined degree of polymerisation (dp) of below about 25 and sulfonylureas and/or a sulfonamide and/or derivatives and/or metabolites thereof used in the treatment of type-2 diabetes meliitus (t2dm).
|Oil soluble polyalkylene glycol lubricant compositions|
A lubricant composition comprising at least 90 wt % of at least one oil soluble polyalkylene glycol (osp), wherein the osp comprises at least 40 wt % units derived from butylene oxide and at least 40 wt % units derived from propylene oxide, initiated by one or more initiators selected from monols, diols, and polyols; and at least 0.05 wt % of at least one anti-wear additive; wherein the lubricant composition exhibits a four ball anti-wear of less than or equal to 0.35 mm and an air release value at 50° c. Of less than or equal to 1 minute is provided..
|Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing 1,2-propanediol, n-propanol, 1,3-propanediol, or glycerol related thereto|
Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as 1,2-propanediol, n-propanol, 1,3-propanediol or glycerol.
|Method for sterilizing microbial cells using polyethylene glycol-based nonionic surfactant|
A method for sterilizing microbial cells is provided. According to the method, microbial cells or a culture containing microbial cells are treated with a polyethylene glycol-based nonionic surfactant so that almost all of the microbial cells are sterilized while the enzyme activity expressed in the microbial cells is maintained at a high level.
|Cmv glycoproteins and recombinant vectors|
This invention also relates to recombinant vectors expressing one or more of the human cmv (hcmv) glycoproteins us2, us3, us6 and us11 or corresponding functional rhesus cmv (rhcmv) homologues rh182, rh184, rh185 or rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products..
|Endoglycosidase from streptococcus pyogenes and methods using it|
The invention provides an endoglycosidase, referred to as endos49 and having the amino acid sequence of seq id no: 1. Endos49 was isolated from streptococcus pyogenes strain nz131 and is a homolog of endos.
|Resist composition, resist pattern-forming method, and resist solvent|
A resist composition includes a polymer that includes an acid-labile group-containing structural unit, a photoacid generator, and a solvent. The solvent includes a compound that includes a ketonic carbonyl group and an alcoholic hydroxyl group.
|Energy storage devices having anodes containing mg and electrolytes utilized therein|
For a metal anode in a battery, the capacity fade is a significant consideration. In energy storage devices having an anode that includes mg, the cycling stability can be improved by an electrolyte having a first salt, a second salt, and an organic solvent.
|Composition comprising chicory extract|
The present invention relates to a chicory extract for allowing reduction or control of body weight or limitation of body weight gain, reduction or limitation of increase of fat storage, of fatty liver, of liver triglycerides level, of hypertriglyceridemia, of glycemia level, of insulinemia level, of insulin resistance, and/or of different factors of metabolic syndrome, and to a composition comprising such an extract.. .
|Dpp-iv inhibitor formulations|
The present invention relates to a pharmaceutical formulation, characterized by comprising a dpp-iv inhibitor and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.. .
|Hydrous adhesive skin patch|
The purpose of the present invention is to provide a hydrous adhesive skin patch which contains lidocaine and can be applied in a uniform thickness easily. This hydrous adhesive skin patch comprises a support and an adhesive agent layer arranged on the support, wherein lidocaine or a pharmacologically acceptable salt thereof, a hydrophilic adhesive agent, and diethylene glycol or a diethylene glycol monoalkyl ether are contained in the adhesive agent layer.
|Ophthalmic composition containing cyclosporine and method for preparing same|
The present invention relates to an ophthalmic composition containing cyclosporine as an active ingredient and comprising propylene glycol, a surfactant, and purified water, and to a method for preparing same. The ophthalmic composition according to the present invention is in the form of a clear and transparent solution, and increases patient compliance due to the absence of side effects, such as cloudy vision or a scorching sensation, and has a high bioavailability due to improved cyclosporine absorbance in the ocular tissue, which is the target organ..
|Herpes simplex virus|
The present invention relates, in general to herpes simplex virus (hsv) and, particular, to antibodies that are specific for glycoprotein d (gd) of hsv. The invention also relates to prophylactic and therapeutic uses of such antibodies..
|Triple acting antimicrobials that are refractory to resistance development|
Multi-drug resistant superbugs are a persistent problem in modern health care. This invention provides an antimicrobial endolysin-lysostaphin triple fusion protein, comprising (1) an endolysin chap endopeptidase domain, (2) an endolysin amidase domain, and (3) a lysostaphin glycyl-glycine endopeptidase domain.
|Compositions, methods and uses for treating solid tumors using lcmv-gp-vsv pseudotype vectors|
Embodiments of the present invention relate to compositions and methods for producing recombinant vsv viruses. In accordance with these embodiments, viral vectors can include a glycoprotein gp of the lymphocyte choriomeningitis virus (lcmv) instead of the g protein of the vsv.
|Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use|
This invention pertains to the field of hyaluronic acid-binding synthetic peptidoglycans and methods of forming and using the same.. .
|Peg-free antiperspirant oil-in-water emulsions having improved feel|
An antiperspirant composition in the form of an oil-in-water emulsion includes a peg-free emulsifier system including selected polyglycerol citrate esters and an n-acylglutamate.. .
|Contrast adjusted anaglyph|
Methods and apparatus for enabling contrast adjustment to anaglyph images are described. Compensation techniques are employed to reduce ghosting artifacts that would otherwise be introduced by contrast adjustments to input images used to generate anaglyphs.
|Polymers useful in agricultural applications|
Methods of coating seeds with polymers and seeds coated with such polymers are disclosed herein. The polymers can be phosphonates, sulfonates, polymers of ethylenically unsaturated carboxylic acids, polyaminopolyethermethylene phosphonate, polysuccinic oligomers, acrylic acid/2-acrylamido-2-methylpropane sulfonic acid, blends of acrylic acid/2-acrylamido-2-methylpropane sulfonic acid with polyaminopolyethermethylene phosphonate, sulfomethylated acrylic acid/acrylamide, blends of sulfomethylated acrylic acid/acrylamide with polyaminopolyethermethylene phosphonate, polymaleic acid, acrylic acid/acrylamide copolymers, polyacrylic acid, trimethylglycine hydrochloride, blends of polyaminopolyethermethylene phosphonate with trimethylglycine hydrochloride, and any combination or salt of such polymers.
|Substance for dyeing keratin fibers, including cationic anthraquinone dyes and fatty acid triglycerides|
The present disclosure provides an agent for coloring keratinic fibers comprising, in a cosmetic carrier (a) at least one compound of formula (i) and (b) at least one fatty acid triglyceride. The present disclosure also provides a method of using such an agent to produce increased shine, an intense color result with improved fastness properties, or reduced selectivity..
|Highly glyphosate-resistant mutated gene, method of modification and use thereof|
Disclosed are a method for obtaining highly glyphosate-resistant g1174 gene mutants through artificial mutation and use thereof. Two or more amino acid mutations are introduced in the amino acid sequence from position 95 to position 114 of protein encoded by g1174 gene, and the highly glyphosate-resistant mutants are selected.
|Alpha-mannosidases from plants and methods for using the same|
The present invention is directed to alpha-mannosidase sequences from plants and the use thereof, especially genomic nucleotide sequences containing the regulatory elements controlling their expression, intron and exon sequences and polynucleotide sequences coding for alpha-mannosidase enzymes. Such plants with modified alpha-mannosidase activity can be used for the production of glycoproteins having an altered saccharide composition of great benefit.
|Blood glucose meter and computer-implemented method for facilitating accurate glycemic control by modeling blood glucose using circadian profiles|
A blood glucose meter and computer-implemented method for facilitating accurate glycemic control by modeling blood glucose using circadian profiles is provided. Anti-hyperglycemic medications are categorized based on similar glucose lowering effects.
|Preparation process of nanocatalysts with (111) crystal facet exposed and process for vapour-phase co oxidative coupling to oxalate|
The invention belongs to the technical field of preparing oxalate in coal to ethylene glycol, aiming at providing a preparation process for nanocatalysts with (111) crystal facet exposed and a process for vapour-phase co oxidative coupling to oxalate. The nanocatalysts with (111) crystal facet exposed comprise carrier, active component and promoter on the carrier, wherein, in term of the weight of the carrier, the active component accounts for 0.05-2% of the weight of the carrier, the weight percentage of metal elements in the promoter is 20% or less.
|Process for fractionating crude triglyceride oil|
The present invention relates to an improved process for fractionating triglyceride oil. The process according to the present invention attains a reproducible crystallization by introducing a controlled temperature profile and ensuing crystal development that reduce the amount of entrapped olein inside the crystals or crystal aggregates.
|Novel process for the preparation of rebaudioside d and other related naturally occurring sweetners|
A novel process for preparation of rebaudioside d (rd), and other related naturally occurring sweeteners is provided. Rd is a natural sweetening agent which can decrease the bitter aftertaste of steviol glycosides.
|Associative acrylic thickening agent containing polyglycerols and its use to increase the open time of thin or thick films|
The present invention relates to new acrylic associative thickening agents which, when polymerized in the presence of particular polyglycerols, ultimately result in an increase of the open time of the paint or of the thick coating in which they are incorporated. By so doing, painters and applicators will have more time to work the paint layers gradually or to correct imperfections such as paint droplets, traces of brushes and filling-knives..
|Telechelic based networks from novel macromonomers, compositions, preparation and uses thereof|
The invention provides highly resilient synthetic hydrogels, which can be prepared, for example, by using the efficient thiol-norbornene chemistry to cross-link hydrophilic poly(ethylene glycol) (peg) and hydrophobic polydimethylsiloxane (pdms) polymer chains. The simple hydrogel system with enhanced mechanical properties is useful in many applications, including in the biomedical field and in the design of protective and corrective wear..
|Copier/printer exterior part using halogen-free flame-retardant resin composition including recycled polycarbonate and recycled polyethylene terephthalate|
A copier/printer exterior part uses a halogen-free flame-retardant resin composition. The halogen-free flame-retardant resin composition includes 5 wt % to 50 wt % of unused polycarbonate, 20 wt % to 63 wt % of recycled polycarbonate 5 wt % to 35 wt % of recycled polyethylene terephthalate, 0.2 wt % to 2 wt % of a styrene-acrylonitrile-glycidyl methacrylate terpolymer, 5 wt % to 15 wt % of a toughener, 10 wt % to 20 wt % of a flame retardant, 0.1 wt % to 0.8 wt % of a flame-retardant antidrip agent, 0.1 wt % to 1 wt % of an antioxidant, and 0.1 wt % to 2 wt % of a lubricant.
|Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof|
There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer..
|Formulations based on solid dispersions|
The present invention relates to formulations comprising a solid dispersion product of an active agent having at least one of a hydrogen bond donor moiety (e.g. Ibuprofen, fenofibric acid or naproxen) and a proton donor moiety and a pharmaceutically acceptable polyvinyllactam polyvinylacetate poly(alkylene glycol) graft copolymer, and to methods for preparing such formulations..
|Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes|
An object of the present invention is to provide a drug that contains a compound for inhibiting neutral lipid accumulation in cardiovascular tissue or cells and has an excellent prophylactic or therapeutic effect on cardiovascular complications of diabetes. The present invention relates to a prophylactic and/or therapeutic agent for cardiovascular complications of diabetes, the agent containing a compound (preferably a medium-chain fatty acid and/or a medium-chain triglyceride) for inhibiting neutral lipid accumulation..
|Solid retard formulations based on solid dispersions|
A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of n-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation..
|Use of quaternary pyridinium salts as vasoprotective agents|
Wherein r is nh2, ch3, or n(h)ch2oh group, and x is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin pgi2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low hdl level.. .
|Imino-sugar c-glycosides, preparation and use thereof|
The present disclosure relates to iminosugar derivatives and processes for the preparation thereof. The disclosed compounds have glycosidase inhibiting properties, and are useful in the treatment of various diseases, such as type 2 diabetes, neurodegenerative diseases or lysosomal storage disorders.
|High-loading water-soluable carrier-linked prodrugs|
The present invention relates to water-soluble carrier-linked prodrugs of formula (i), wherein b, a and hyp form the carrier, b is a branching core, each a is independently a poly(ethylene glycol)-based polymeric chain, each hyp is independently a branched moiety, each sp is independently a spacer moiety, each l is independently a reversible prodrug linker moiety, each d is independently a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use as medicament or diagnostic, and methods of treatment..
|Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives|
The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms..
|Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus|
The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of hiv, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from pparγ2, lpl and αp2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual.
|System and method for cell-type specific comparative analyses of different genotypes to identify resistance genes|
Glycine max l. Merr.
Popular terms: [SEARCH]
Gly topics: Door Assembly, Swimming Goggles, Transverse, Alkoxylate, Fluoropolymer, Air Cleaning, Rotor Shaft, Aspect Ratio, Disconnect, Synchronization, Remote Control, Ethylene Glycol, Surfactant, Combustion, Steviol Glycosides
Follow us on Twitter
This listing is a sample listing of patent applications related to Gly for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Gly with additional patents listed. Browse our RSS directory or Search for other possible listings.